Immunoglobulin Support for Patients with Hematologic Malignancies: When Should You Discuss Starting, How Should You Dose, and When Is It Safe to Consider Stopping – Webinar

Home > Immunoglobulin Support for Patients with Hematologic Malignancies: When Should You Discuss Starting, How Should You Dose, and When Is It Safe to Consider Stopping – Webinar

07 Nov Immunoglobulin Support for Patients with Hematologic Malignancies: When Should You Discuss Starting, How Should You Dose, and When Is It Safe to Consider Stopping – Webinar

Posted at 13:29h in by

In this video we will:

1.Discuss the evidence from clinical trials for IVIG and SCIG for patients with hematologic malignancies and secondary hypogammaglobulinemia

2.Estimate the cost of 1 year of IVIG or SCIG for the healthcare system

3.Understand the evidence gap to be addressed by the RATIONAL-PT and IRIS trials

Case Study Content